Saman Sadeghi

Saman Sadeghi

Auto-generated profile, based on publicly available information

Saman Sadeghi

Department of Chemistry and Chemical Biology, McMaster University, Hamilton, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2018 in ChemElectroChem
Verified
Journal Article
Closed access
PDF file
MBMehrdad Balandeh
Mehrdad Balandeh
ARAlejandra Rios
Alejandra Rios
NANathanael Allison
Nathanael Allison
DSDaniela Shirazi
Daniela Shirazi
AGAdrian Gomez
Adrian Gomez
SSSaman Sadeghi
Saman Sadeghi

21 September 2024 in Journal of Fluorine Chemistry
Verified
Journal Article
Open access
TKTomoyuki Kurioka
Tomoyuki Kurioka
YLYingqing Lu
Yingqing Lu
JJJason Jones
Jason Jones
XWXueyi Wang
Xueyi Wang
DHDaniel Hernández-Valdés
Daniel Hernández-Valdés
SSSaman Sadeghi
Saman Sadeghi

7 August 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RSRowan Swann
Rowan Swann
DHDaniel Hernández-Valdés
Daniel Hernández-Valdés
LSLuis Rafael Silva
Luis Rafael Silva
YMYusra Mahmood Marfatia
Yusra Mahmood Marfatia
MEMohamed E. El-Zaria
Mohamed E. El-Zaria
SSSaman Sadeghi
Saman Sadeghi
The development of a non-invasive infection-specific diagnostic probe holds the potential to vastly improve early-stage detection of infection, enabling precise therapeutic intervention and potentially reducing the incidence of antibiotic resistance. Towards this goal, a commercially available bacteria-targeting Zinc(II)-dipicolylamine (ZnDPA)-derived fluorophore, PSVue794, was assessed as a photoacoustic (PA) imaging probe (PIP). A radiolabeled version of the dye, [99mTc]Tc-PSVue794, was developed to facilitate quantitative biodistribution studies beyond optical imaging methods, which showed a target-to-non-target ratio of 10.1 ± 1.1, 12 h post-injection. The ability of the PIP to differentiate between bacterial infection, sterile inflammation, and healthy tissue in a mouse model, was then evaluated via PA imaging. The PA signal in sites of sterile inflammation (0.062 ± 0.012 a.u.) was not statistically different from that of the background (0.058 ± 0.006 a.u.). In contrast, high PA signal was detected at sites of bacterial infection (0.176 ± 0.011 a.u.) as compared to background (0.081 ± 0.04 a.u., where P ≤ 0.03). This work demonstrates the potential of utilizing established fluorophores towards PAI and utilizing PAI as a modality in the distinction of bacterial infection from sites of sterile inflammation.

22 May 2025 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
KWKevin Wyszatko
Kevin Wyszatko
NJNancy Janzen
Nancy Janzen
NLNapoleon Law
Napoleon Law
MVManuela Ventura
Manuela Ventura
TKTeesha Komal
Teesha Komal
SSSaman Sadeghi
Saman Sadeghi

18 March 2024 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
KWKevin Wyszatko
Kevin Wyszatko
MCMelissa Chassé
Melissa Chassé
NJNancy Janzen
Nancy Janzen
LSLuis Rafael Silva
Luis Rafael Silva
LKLuke Kwon
Luke Kwon
SSSaman Sadeghi
Saman Sadeghi
Background: Cancer stem cells play an important role in driving tumor growth and treatment resistance, which makes them a promising therapeutic target to prevent cancer recurrence. Emerging cancer stem cell-targeted therapies would benefit from companion diagnostic imaging probes to aid in patient selection and monitoring response to therapy. To this end, zirconium-89-radiolabeled immunoPET probes that target the cancer stem cell-antigen CD133 were developed using fully human antibody and antibody scFv-Fc scaffolds. Results: ImmunoPET probes [ 89 Zr]-DFO-RW03 IgG (CA = 0.7 ± 0.1), [ 89 Zr]-DFO-RW03 IgG (CA = 3.0 ± 0.3), and [ 89 Zr]-DFO-RW03 scFv − Fc (CA = 2.9 ± 0.3) were radiolabeled with zirconium-89 (radiochemical yield 42 ± 5%, 97 ± 2%, 86 ± 12%, respectively) and each was isolated in > 97% radiochemical purity with specific activities of 120 ± 30, 270 ± 90, and 200 ± 60 MBq/mg, respectively. In vitro binding assays showed a low-nanomolar binding affinity of 0.6 to 1.1 nM (95% CI) for DFO-RW03 IgG (CA = 0.7 ± 0.1), 0.3 to 1.9 nM (95% CI) for DFO-RW03 IgG (CA = 3.0 ± 0.3), and 1.5 to 3.3 nM (95% CI) for DFO-RW03 scFv − Fc (C/A = 0.3). Biodistribution studies found that [ 89 Zr]-DFO-RW03 scFv − Fc (CA = 2.9 ± 0.3) exhibited the highest tumor uptake (23 ± 4, 21 ± 2, and 23 ± 4%ID/g at 24, 48, and 72 h, respectively) and showed low uptake (< 6%ID/g) in all off-target organs at each timepoint (24, 48, and 72 h). Comparatively, [ 89 Zr]-DFO-RW03 IgG (CA = 0.7 ± 0.1) and [ 89 Zr]-DFO-RW03 IgG (CA = 3.0 ± 0.3) both reached maximum tumor uptake (16 ± 3%ID/g and 16 ± 2%ID/g, respectively) at 96 h p.i. and showed higher liver uptake (10.2 ± 3%ID/g and 15 ± 3%ID/g, respectively) at that timepoint. Region of interest analysis to assess PET images of mice administered [ 89 Zr]-DFO-RW03 scFv − Fc (CA = 2.9 ± 0.3) showed that this probe reached a maximum tumor uptake of 22 ± 1%ID/cc at 96 h, providing a tumor-to-liver ratio that exceeded 1:1 at 48 h p.i. Antibody-antigen mediated tumor uptake was demonstrated through biodistribution and PET imaging studies, where for each probe, co-injection of excess unlabeled RW03 IgG resulted in > 60% reduced tumor uptake. Conclusions: Fully human CD133-targeted immunoPET probes [ 89 Zr]-DFO-RW03 IgG and [ 89 Zr]-DFO-RW03 scFv − Fc accumulate in CD133-expressing tumors to enable their delineation through PET imaging. Having identified [ 89 Zr]-DFO-RW03 scFv − Fc (CA = 2.9 ± 0.3) as the most attractive construct for CD133-expressing tumor delineation, the next step is to evaluate this probe using patient-derived tumor models to test its detection limit prior to clinical translation.

1 April 2026 in Canadian Journal of Chemistry
Verified
Journal Article
Closed access
PPPamela Penawou
Pamela Penawou
CZCarol Yunfei Zheng
Carol Yunfei Zheng
AGAfaf R. Genady
Afaf R. Genady
LSLuis Rafael Silva
Luis Rafael Silva
AIAyman A. Ibrahim
Ayman A. Ibrahim
SSSaman Sadeghi
Saman Sadeghi
Fibroblast activation protein (FAP) is highly expressed on cancer-associated fibroblasts, making it an attractive target for oncological imaging and therapy. FAPI-74, a FAP inhibitor in phase II clinical evaluation with 18 F as a positron emission tomography tracer, has exhibited high tumour uptake and specificity. Development of single photon emission computed tomography (SPECT) analogue [ 99m Tc]Tc-FAPI-74 offers advantages of lower cost and accessibility through established SPECT infrastructure. Herein, we report the radiolabeling and characterization of FAPI-74 with 99m Tc and [ 18 F]AlF, and comparative evaluation of their binding properties and biodistribution in FAP-positive and FAP-negative xenograft mouse models. FAPI-74 was radiolabeled with [ 99m Tc]Tc-tricarbonyl, achieving radiochemical conversion (RCC) of 20% and 0.32 GBq/µmol molar activity (Am). Comparatively, [ 18 F]AlF labeling resulted in 75% RCC, and 3.33 GBq/µmol Am. Both tracers exhibited >99% radiochemical purity. In vitro binding to FAP+ cells was comparable between [ 99m Tc]Tc-FAPI-74 and [ 18 F]AlF-FAPI-74 (29.9 ± 4.7% vs. 31.4 ± 11.0% binding and K D values of 14.6 nM vs. 5.09 nM). In vivo, tumour uptake in HT29 xenografts was similar (2.14 ± 0.29 vs. 1.59 ± 0.12 %ID/g) with a %ID/g of <0.5 in the blocked group of both ligands. However, in HEK-293-FAP+ xenografts, tumour uptake was markedly lower for [ 99m Tc]Tc-FAPI-74 (3.17 ± 0.26 vs. 25.73 ± 4.49 %ID/g). [ 99m Tc]Tc-FAPI-74 demonstrates comparable in vitro performance to [ 18 F]AlF-FAPI-74, with similar binding and K D values, but its higher lipophilicity limits its clinical competitiveness due to low tumour uptake of [ 99m Tc]Tc-FAPI-74. Nonetheless, its FAP-specific uptake in mouse models, together with the availability of FAPI-74 and facile 99m Tc radiolabeling, highlights its potential for imaging tumours outside the hepatobiliary system. Future SPECT FAP tracers should improve hydrophilicity to minimize hepatobiliary clearance and improve tumour specificity.